180 Life Sciences Corp.
ATNF
$3.00
$0.8740.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.62% | -37.33% | -55.81% | -63.42% | -53.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.34% | -38.65% | -53.07% | -63.94% | -50.89% |
| Operating Income | 27.34% | 38.65% | 53.07% | 63.94% | 50.89% |
| Income Before Tax | 36.23% | 58.24% | 70.99% | 92.85% | 71.68% |
| Income Tax Expenses | 87.40% | 87.40% | 87.40% | 99.87% | -149.22% |
| Earnings from Continuing Operations | 26.65% | 54.03% | 69.06% | 92.28% | 75.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.65% | 54.03% | 69.06% | 92.28% | 75.71% |
| EBIT | 27.34% | 38.65% | 53.07% | 63.94% | 50.89% |
| EBITDA | 27.14% | 38.66% | 53.27% | 64.17% | 51.19% |
| EPS Basic | 54.64% | 70.01% | 78.96% | 98.19% | 93.47% |
| Normalized Basic EPS | 63.75% | 82.85% | 88.75% | 94.13% | 87.71% |
| EPS Diluted | 54.65% | 70.01% | 78.96% | 98.18% | 93.46% |
| Normalized Diluted EPS | 63.75% | 82.85% | 88.75% | 94.13% | 87.71% |
| Average Basic Shares Outstanding | 336.74% | 235.60% | 141.75% | 213.46% | 275.01% |
| Average Diluted Shares Outstanding | 336.74% | 235.60% | 141.75% | 213.46% | 275.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |